Search Results - "BOEDER, C"

Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia by Ciaraldi, Theodore P., Boeder, Schafer C., Mudaliar, Sunder R., Giovannetti, Erin R., Henry, Robert R., Pettus, Jeremy H.

“…Aim To determine the effects of astaxanthin treatment on lipids, cardiovascular disease (CVD) markers, glucose tolerance, insulin action and inflammation in…”
Get full text

148-OR: CGM Time Below Range Predicts Epinephrine Response to Hypoglycemia in Patients with Type 1 Diabetes by THOMAS, ROBERT L., GREGORY, JUSTIN M., GIOVANNETTI, ERIN R., BOEDER, SCHAFER C., PETTUS, JEREMY

“…Identifying T1D patients with impaired awareness of hypoglycemia (IAH) is essential, as these patients are at ~10-fold risk of severe hypoglycemia. Defining…”
Get full text

SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes by Boeder, Schafer C, Gregory, Justin M, Giovannetti, Erin R, Pettus, Jeremy H

“…Individuals with type 1 diabetes have an impaired glucagon counterregulatory response to hypoglycemia. Sodium-glucose cotransporter (SGLT) inhibitors increase…”
Get full text

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial by Pettus, Jeremy, Boeder, Schafer C., Christiansen, Mark P., Denham, Douglas S., Bailey, Timothy S., Akturk, Halis K., Klaff, Leslie J., Rosenstock, Julio, Cheng, Mickie H. M., Bode, Bruce W., Bautista, Edgar D., Xu, Ren, Yan, Hai, Thai, Dung, Garg, Satish K., Klein, Samuel

“…Hyperglucagonemia contributes to hyperglycemia in patients with type 1 diabetes (T1D); however, novel therapeutics that block glucagon action could improve…”
Get full text

Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial by Boeder, Schafer C, Thomas, Robert L, Le Roux, Melissa J, Giovannetti, Erin R, Gregory, Justin M, Pettus, Jeremy H

“…To examine the effects of insulin-adjunctive therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon receptor antagonist (GRA) on…”
Get full text

Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes by Thomas, Robert L, Boeder, Schafer C, Hamidi, Vala, Giovannetti, Erin R, Gregory, Justin M, Pettus, Jeremy H

Get full text

267-OR: ADA Presidents' Select Abstract: Combining an SGLT Inhibitor with a Glucagon Receptor Agonist (GRA) in Subjects with Type 1 Diabetes—A Randomized Clinical Trial by BOEDER, SCHAFER C., ROUX, MELISSA J. LE, GIOVANNETTI, ERIN R., ARMSTRONG, ADRIENNE, CARTER, LESLIE, THOMAS, ROBERT L., GREGORY, JUSTIN M., PETTUS, JEREMY

“…SGLTi treatment improves glycemic control and reduces insulin dosing but increases the risk of diabetic ketoacidosis (DKA). Combination therapy (SGLTi + GRA)…”
Get full text

835-P: The Hepatoselective Glucokinase Activator (GKA) TTP399 Does Not Increase Risk of Ketoacidosis in Type 1 Diabetes (T1D) by KLEIN, KLARA, BOEDER, SCHAFER C., FREEMAN, JENNIFER L., MADDURI, SUPRADEEP, GIOVANNETTI, ERIN R., VALCARCE, CARMEN, BUSE, JOHN B., PETTUS, JEREMY

“…Identification of adjunctive, oral pharmacotherapies to treat T1D has been limited by risk of DKA. TTP399, an oral hepatoselective GKA, significantly improves…”
Get full text

128-LB: Effects of Glucagon Receptor Antagonism (GRA) on Ketone Body Formation during Insulinopenia in Type 1 Diabetes (T1D) by BOEDER, SCHAFER C., INES, DANIEL G., CARTER, LESLIE, GIOVANNETTI, ERIN R., ARMSTRONG, DEBRA, BURKE, PAIVI, PETTUS, JEREMY

“…Background: Diabetic ketoacidosis is a common and life-threatening complication of T1D. Glucagon stimulates ketogenesis via peripheral lipolysis and hepatic…”
Get full text

Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial by Pettus, Jeremy, Boeder, Schafer C., Christiansen, Mark P., Denham, Douglas S., Bailey, Timothy S., Akturk, Halis K., Klaff, Leslie J., Rosenstock, Julio, Cheng, Mickie H. M., Bode, Bruce W., Bautista, Edgar D., Xu, Ren, Yan, Hai, Thai, Dung, Garg, Satish K., Klein, Samuel

Get full text

322-OR: SGLT2 Inhibition Has No Effect on the Counterregulatory Response to Hypoglycemia in Subjects with Type 1 Diabetes (T1D) by BOEDER, SCHAFER C., INES, DANIEL G., GIOVANNETTI, ERIN R., HAMIDI, VALA, BURKE, PAIVI M., ARMSTRONG, ADRIENNE, CARTER, LESLIE, PETTUS, JEREMY

“…Individuals with T1D have an ineffective glucagon response to low glucose levels which predisposes them to episodes of hypoglycemia. SGLT-2 inhibitors (SGLT2i)…”
Get full text

Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes by Klein, Klara R., Boeder, Schafer C., Freeman, Jennifer L. R., Dunn, Imogene, Dvergsten, Chris, Madduri, Supradeep, Giovannetti, Erin R., Valcarce, Carmen, Buse, John B., Pettus, Jeremy H.

“…Aims To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type…”
Get full text

236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial by PETTUS, JEREMY, BOEDER, SCHAFER C., CHRISTIANSEN, MARK P., DENHAM, DOUGLAS S., BAILEY, TIMOTHY S., AKTURK, HALIS K., KLAFF, LESLIE J., ROSENSTOCK, JULIO, CHENG, MICKIE H.M., BODE, BRUCE W., BAUTISTA, EDGAR D., YAN, HAI, THAI, DUNG, GARG, SATISH K., KLEIN, SAMUEL

“…Abnormal regulation of glucagon secretion contributes to impaired glycemic control in patients with T1D. We conducted two 12-week, double-blind, randomized,…”
Get full text

Magnetic storm acceleration of radiation belt electrons observed by the Scintillating Fibre Detector (SFD) onboard EQUATOR-S by Cyamukungu, M., Lippens, C., Adams, L., Nickson, R., Boeder, C., Pierrard, V., Daly, E., Grégoire, Gh, Lemaire, J.

“…On the basis of the currents induced by electron fluxes in the Scintillating Fibre Detector (SFD) onboard the EQUATOR-S satellite launched on 2 December 1997,…”
Get full text

Magnetic storm acceleration of radiation belt electrons observed by the Scintillating Fibre Detector (SFD) onboard EQUATOR-S: Equator-S - First results by CYAMUKUNGU, M, LIPPENS, C, ADAMS, L, NICKSON, R, BOEDER, C, PIERRARD, V, DALY, E, GREGOIRE, G, LEMAIRE, J

Get full text

Evidence for glycine modulation of excitatory synaptic inputs to retinal ganglion cells by Lukasiewicz, PD, Roeder, RC

“…The actions of glycine on the NMDA receptor-mediated synaptic responses of ganglion cells were studied in the tiger salamander retinal slice. Ganglion cell…”
Get full text

Preparation of simple chiral allenes. Reaction of propargylic carbamates with lithium dialkylcuprates by Pirkle, W. H, Boeder, Charles W

Get full text

Estimation of allene optical purities by nuclear magnetic resonance by Pirkle, W. H, Boeder, Charles W

Get full text

Synthesis and absolute configuration of (-)-methyl (E)-2,4,5-tetradecatrienoate, the sex attractant of the male dried bean weevil by Pirkle, W. H, Boeder, Charles W

Get full text

Medical panacea of the 17th century by BODER, H C

Get more information